Seeking Alpha

St. Jude Medical, Inc. (STJ)

  • Dec. 11, 2014, 8:21 AM
    • St. Jude Medical's (NYSE:STJ) Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P) is now CE Mark-approved in Europe. The Quadra Allure MP is the only quadripolar CRT-P with the MultiPoint Pacing option, which has been shown to enhance patients' responses to CRT.
    • The product is designed to work with the Quartet LV lead which has four electrodes, enabling more flexibility in pacing configurations.
    | Comment!
  • Nov. 24, 2014, 3:43 PM
    • Twenty-two spinoffs have been completed in 2014, the most in a decade, and another 28 have been announced. Among the catalysts are activist investors, so Credit Suisse screened for companies with multiple business segments, slow growth, and stocks trading for lower multiples than peers, in other words, "good, quality companies that are struggling to grow."
    • The list is heavy on big media names like Time Warner (NYSE:TWX) and Twenty-First Century Fox (NASDAQ:FOXA), big tech like Oracle (NYSE:ORCL), Symantec (NASDAQ:SYMC), and IBM, and big industry like Lockheed Martin (NYSE:LMT), Ingersoll-Rand (NYSE:IR), and Raytheon (NYSE:RTN), but just two financial names - Travelers (NYSE:TRV) and Torchmark (NYSE:TMK).
  • Nov. 19, 2014, 7:48 AM
    • During the scientific sessions at the American Heart Association meeting in Chicago, investigators presented a retrospective data analysis from the CHAMPION clinical trial evaluating the safety and efficacy of St. Jude Medical's (NYSE:STJ) CardioMEMS HF System in patients with New York Heart Association Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months.
    • The device is implanted in the pulmonary artery (PA) during a minimally invasive procedure to directly measure PA pressure via a miniaturized wireless monitoring sensor. Measuring PA pressure allows clinicians to proactively manage treatment with medication changes for patients with worsening HF before visible symptoms occur. The system allows patients to transmit PA pressure data from their homes to their doctors enabling them to adjust the meds to reduce the likelihood of hospitalization.
    • In patients aged 65 and older, patients implanted with the CardioMEMS HF Systems had 58% fewer all-cause hospital readmissions and 78% fewer HF readmissions compared to standard-of-care medical management. The results suggest that the use of the CardioMEMS HF Systems could reduce a hospital's risk of government-imposed financial penalties from patient readmissions with 30 days of treatment.
    | Comment!
  • Nov. 10, 2014, 10:49 AM
    • The Japanese Ministry of Health, Labour and Welfare approves Medtronic's (MDT +0.1%) Evera SureScan implantable cardioverter-defibrillator (ICD) for magnetic resonance imaging (MRI) scans positioned on any region of the body. The commercial launch is underway.
    • Evera MRI is available in both single chamber and dual chamber ICDs.
    • Until the availability of MR-Conditional ICDs, patients with the devices had been contraindicated from receiving MRI scans because of the potential interactions between the MRI and device function.
    • Evera MRI is not yet approved in the U.S.
    • Related tickers: (STJ +0.7%)(BSX +1.6%)
    | Comment!
  • Oct. 27, 2014, 11:41 AM
    • The FDA approves St. Jude Medical's (STJ -0.3%) TactiCath Quartz irrigated ablation catheter. The product gives physicians a real-time objective measure of the force that the catheter applies to a patient's heart wall during an ablation procedure. The technology is associated with a reduction in the rate of atrial fibrillation recurrence when optimal treatment measures are used.
    • Related tickers: (BCR +1.2%)(MDT -0.1%)(JNJ +0.9%)(BSX +0.8%)(HNSN +2.1%)(ABT -0.6%)
    | Comment!
  • Oct. 21, 2014, 5:17 PM
    • St. Jude Medical (NYSE:STJ) declares $0.27/share quarterly dividend, in line with previous.
    • Forward yield 1.80%
    • Payable Jan 30; for shareholders of record Dec. 31; ex-div Dec. 29.
    | Comment!
  • Oct. 15, 2014, 8:30 AM
    • St. Jude Medical (NYSE:STJ) Q3 revenue growth by selected line item:
    • Leaders: Intl Neuromodulation: +14.3%; International Atrial Fibrillation: +11.5%; WW Atrial Fibrillation: +7.7%; U.S. Cardiovascular: +5.3%.
    • Laggards: International ICD: -3.0%; International Cardiac Rhythm Management: -2.2%; International Pacemakers: -1.3%; U.S. Neuromodulation: -1.3%.
    | Comment!
  • Oct. 15, 2014, 8:20 AM
    • St. Jude Medical (NYSE:STJ) Q3 results: Revenues: $1,372M (+2.5%); International: $706M (+2.0%); U.S.: $666M (+3.1%); WW Cardiac Rhythm Management (CRM): $688M (-0.3%); International CRM: $315M (-2.2%); U.S. CRM: $373M (+3.6%); WW ICD: $422M (+1.0%); Intl ICD: $160M (-3.0%); U.S. ICD: $262M (+3.6%); WW Pacemakers: $266M (+0.8%); Intl Pacemakers: $155M (-1.3%); U.S. Pacemakers: $111M (+3.7%); WW AF: $253M (+7.7%); Intl AF: $155M (+11.5%); U.S. AF: $98M (+2.1%); WW Cardiovascular: $324M (+2.2%); Intl Cardiovascular: $204M (+0.5%); U.S. Cardiovascular: $120M (+5.3%); WW Neuromodulation: $107M (+2.9%); Intl Neuromodulation:  $32M (+14.3%); U.S. Neuromodulation: $75M (-1.3%).
    • COGS: $412M (+7.0%); R&D Expense: $169M (-1.7%); SG&A Expense: $476M (+5.3%); Net Income: $238M (-9.2%); EPS: $0.82 (-8.9%); Quick Assets: $1,294M (+3.9%).
    • Gross Profit: $960M (+0.7%); COGS: 30.0% (+4.4%); Gross Margin: 70.0% (-1.8%); Operating Profit: $315M (-4.3%); Operating Earnings Yield: 23.0% (-6.6%); Net Earnings Yield: 17.3% (-11.4%).
    • 2014 guidance: Revenues: $5.568B - 5.648B from $5.64B - 5.76B; EPS: $3.97 - 3.99 from $3.96 - 4.01.
    • Q4 guidance: Revenues: $1.385B - 1.465B; EPS: $1.02 - 1.04.
  • Oct. 15, 2014, 7:34 AM
    • St. Jude Medical (NYSE:STJ): Q3 EPS of $0.97 beats by $0.01.
    • Revenue of $1.37B (+2.2% Y/Y) misses by $10M.
    • Shares +0.15% PM.
    • Press Release
    | Comment!
  • Oct. 14, 2014, 5:30 PM
  • Oct. 1, 2014, 6:23 PM
    • ST. Jude Medical (STJ +0.4%will report Q3 results on Wednesday, October 15 before the open. The conference call will begin at 6:30 am CT.
    • Consensus view is EPS of $0.96 on revenues of $1.39B.
    | Comment!
  • Oct. 1, 2014, 4:37 PM
    • St. Jude Medical (STJ +0.4%) will report Q3 results on October 15 before the open. The conference call will begin at 7:00 am CT.
    • Consensus view is EPS of $0.96 on revenues of $1.39B.
    | Comment!
  • Oct. 1, 2014, 10:05 AM
    • In response to the ever-increasing risk of security breaches, the FDA issues final guidance for device makers entitled, "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices." The agency recommends that device manufacturers consider cybersecurity risks at part of the design and development of their products and submit documentation to the FDA about the risks identified and the controls in place to mitigate them. The agency also recommends that companies submit their plans for patches and upgrades to device operating systems and medical software.
    • The agency will hold a public workshop on October 21, 2014 to discuss how all the constituency groups can work together to improve cybersecurity in medical devices and protect the public health.
    • Some related tickers: (MDT -0.2%)(BSX -0.9%)(STJ -0.3%)(ABT -0.6%)(JNJ -1.4%)(OTCQX:RHHBY +0.1%)
    | 1 Comment
  • Sep. 15, 2014, 11:51 AM
    | Comment!
  • Aug. 27, 2014, 12:46 PM
    • The FDA notifies St. Jude Medical (STJ +0.1%) that the issues cited in its warning letter regarding its Plano, TX manufacturing facility have been resolved. The agency issued the letter on June 26, 2009 after an on-site inspection identified cGMP non-conformities.
    | Comment!
  • Jul. 29, 2014, 6:21 PM
    • St. Jude Medical (NYSE:STJ) declares $0.27/share quarterly dividend, in line with previous.
    • Forward yield 1.64%
    • Payable Oct. 31; for shareholders of record Sept. 30; ex-div Sept. 26.
    | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.